These findings warrant the clinical testing of PeptiCRAd-1 in combination with ICIs against the PD-1/PD-L1 pathway for the treatment of NY-ESO-1- and MAGE-A3-expressing cancers, such as TNBC, melanoma, non-small cell lung cancer, and sarcoma. Here, MAGEA3 is linked to cancer.